Atria Investments Inc Sells 1,309 Shares of Smith & Nephew plc (NYSE:SNN)

Atria Investments Inc decreased its position in shares of Smith & Nephew plc (NYSE:SNN) by 5.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,665 shares of the medical equipment provider’s stock after selling 1,309 shares during the period. Atria Investments Inc’s holdings in Smith & Nephew were worth $675,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of Smith & Nephew during the third quarter valued at about $792,000. Lorne Steinberg Wealth Management Inc. grew its position in Smith & Nephew by 53.6% in the second quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider’s stock worth $5,725,000 after acquiring an additional 80,650 shares in the last quarter. Clearbridge Investments LLC purchased a new position in Smith & Nephew in the first quarter worth about $2,612,000. Sanctuary Advisors LLC purchased a new position in Smith & Nephew in the second quarter worth about $627,000. Finally, Bank of Montreal Can grew its position in Smith & Nephew by 355.8% in the second quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock worth $31,059,000 after acquiring an additional 964,762 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Analysts Set New Price Targets

SNN has been the subject of several recent research reports. Berenberg Bank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th. StockNews.com lowered Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Smith & Nephew Stock Performance

Shares of NYSE:SNN opened at $25.51 on Wednesday. Smith & Nephew plc has a 1 year low of $23.65 and a 1 year high of $31.72. The business has a 50 day simple moving average of $28.49 and a two-hundred day simple moving average of $27.89. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.